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Abstract
Background
To work towards reaching the WHO goal of eliminating soil-transmitted helminth (STH)
infections as a public health problem, the total number of children receiving anthelmintic
drugs has strongly increased over the past few years. However, as drug pressure levels
rise, the development of anthelmintic drug resistance (AR) is more and more likely to
appear. Currently, any global surveillance system to monitor drug efficacy and the emer-
gence of possible AR is lacking. Consequently, it remains unclear to what extent the efficacy
of drugs may have dropped and whether AR is already present. The overall aim of this study
is to recommend the best diagnostic methods to monitor drug efficacy and molecular mark-
ers to assess the emergence of AR in STH control programs.
Methods
A series of drug efficacy trials will be performed in four STH endemic countries with varying
drug pressure (Ethiopia and Brazil: low drug pressure, Lao PDR: moderate drug pressure
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and Tanzania: high drug pressure). These trials are designed to assess the efficacy of a sin-
gle oral dose of 400 mg albendazole (ALB) against STH infections in school-aged children
(SAC) by microscopic (duplicate Kato-Katz thick smear, Mini-FLOTAC and FECPAKG2) and
molecular stool-based diagnostic methods (quantitative PCR (qPCR)). Data will be collected
on the cost of the materials used, as well as the time required to prepare and examine stool
samples for the different diagnostic methods. Following qPCR, DNA samples will also be
submitted for pyrosequencing to assess the presence and prevalence of single nucleotide
polymorphisms (SNPs) in the β-tubulin gene. These SNPs are known to be linked to AR in
animal STHs.
Discussion
The results obtained by these trials will provide robust evidence regarding the cost-effi-
ciency and diagnostic performance of the different stool-based diagnostic methods for the
assessment of drug efficacy in control programs. The assessment of associations between
the frequency of SNPs in the β-tubulin gene and the history of drug pressure and drug effi-
cacy will allow the validation of these SNPs as a marker for AR in human STHs.
Trial registration
The trial was retrospectively registered the 7th of March 2018 on Clinicaltrials.gov (ID:
NCT03465488).
Author summary
Soil-transmitted helminths (STHs) affect 1.4 billion people worldwide and cause signifi-
cant morbidity when the intensity of infection is high. Currently, these infections are con-
trolled in school-aged children by preventive chemotherapy with the benzimidazole drugs
albendazole (ALB) or mebendazole (MEB). However, for the success of these control pro-
grams, it is essential to keep track of the efficacy of these drugs and to screen parasite pop-
ulations for a possible rise of anthelmintic resistance (AR). In this light, a series of trials
will be performed to assess the efficacy of ALB treatment against STH in four endemic
countries with varying drug pressure. Both microscopic and molecular stool-based diag-
nostic methods will be used to evaluate drug efficacy. DNA samples will also be analysed
for the presence and prevalence of mutations in a gene that was previously linked to AR in
animal STHs. The results of these trials will provide evidence on the efficacy of ALB, help
select the optimal diagnostic method to assess drug efficacy and provide information
regarding the usefulness of genetic markers for AR detection in human STHs.
Introduction
Soil-transmitted helminths (STHs) include Ascaris lumbricoides, Trichuris trichiura, and two
hookworm species, namely Necator americanus and Ancylostoma duodenale. Global estimates
indicate that more than 1.4 billion people are infected with at least one of the four STH species
[1]. They are responsible for an estimated 3.3 million disability-adjusted life years (DALYs) of
which 1.2 million occurred in children which is the highest burden among all neglected tropi-
cal diseases (NTDs) [2]. Preventive chemotherapy (PC) is the main strategy to control the
Stool-based diagnostics and molecular markers to assess reduced efficacy and resistance
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morbidity caused by STHs. This entails the periodic administration of a single, oral dose of
albendazole (ALB; 400 mg) or mebendazole (MEB; 500 mg) mainly to preschool-aged (pre-
SAC) and school-aged children (SAC) through a school-based PC programs [3]. However, as
part of the control program for lymphatic filariasis—another NTD which share geographical
distribution with STHs—ALB is also co-administered with ivermectin to the whole commu-
nity [4, 5]. Powered by the London Declaration on NTDs, the global coverage of children in
PC programs has increased from ~30% in 2011 to 63.6% in 2016 [6], and, if the goal of cover-
ing at least 75% of children by 2020 will be reached, over 900,000 DALYs will be averted [7].
The laudable long-term aim is to eliminate STHs as a public health problem, and to eventually
declare targeted geographical areas free of infections [8].
However, this high level of drug pressure makes PC programs highly vulnerable to the
development of anthelmintic resistance (AR). First, we are relying on two drugs (ALB and
MEB) of the same class (benzimidazole (BZ) drugs), and with the same mode of action (the
inhibition of the polymerization of microtubules). Hence the emergence of AR is likely to
occur as drug donations expand. This has been substantiated in veterinary medicine [9–11],
where AR has developed within a decade of the introduction of every anthelmintic class [12].
Moreover, the development of AR against one BZ drug would most likely be accompanied by
poor anthelmintic drug efficacy of the other BZ drug. Second, drugs are administered in single
doses and, although a single dose is operationally justified, it never achieves 100% efficacy [13–
16]. Consequently, this practice may further select for the development of AR when subopti-
mal doses are widely applied over a significant period. in light of breaking transmission of soil-
transmitted helminthiasis there is growing interest to move from a school-based towards a
community-based approach, which will further reduce the worm population that is not
exposed to drugs [17, 18]. Finally, few anthelmintic drugs are licensed for the treatment of
STH infections in humans [19, 20]. Thus, should AR against BZ drugs eventually emerge and
spread, PC-based control of STHs will be even more limited than at present with few accept-
able alternative options. This re-enforces the urgent necessity for increased accessibility of
anthelmintic drugs of different anthelmintic classes and thoroughly designed surveillance sys-
tems that allow for the detection of any changes in anthelmintic drug efficacy arising through
the evolution of AR in these helminths.
In 2013, WHO developed a manual to evaluate drug efficacy (WHO 2013). And although a
number of countries used this manual to evaluate the efficacy of the anthelminthic used in
their programme, a systematic surveillance system to monitor drug efficacy and emergence of
AR is lacking. One of the main reasons for this lack of monitoring systems is the absence of a
framework that guides and supports health-care decision makers in planning, performing and
reporting surveys. The development of such a framework is not straightforward [21]. More-
over, PC programs typically operate in resource-constrained settings, and therefore it is indis-
pensable that health-care decision makers have some pliancy to minimize financial and
technical resources, while assuring a reliable assessment of the drug efficacy and spread of AR
[22–25]. Important obstacles to globally monitor patterns of changing drug efficacy and emer-
gence of AR are (i) the need for diagnostic laboratories with experienced technicians to per-
form the surveys, and experienced staff to analyze and report the data; (ii) the absence of a
quality assurance system that guarantees data of high quality; (iii) a validated marker linked to
AR; (iv) on-site diagnostic methods that allow for early detection of AR, and (v) the lack of
overall guidance in designing surveys to monitor drug efficacy in PC programs.
To conclude, AR is a real threat for PC programs targeting human STHs. To establish a sur-
veillance system and to further ensure the efficacy of the administered drugs, there is a need
for (i) diagnostic methods that effectively mitigate important obstacles of performing, analys-
ing and reporting drug efficacy surveys in resource poor settings, and a validated molecular
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marker to detect emergence of AR at an early stage, (ii) a surveillance system that monitors
global patterns of drug efficacy and AR and (iii) tools to plan routine AR monitoring, and to
follow-up global changes in drug efficacy and spread of AR over time. Each of the aforemen-
tioned needs will be addressed in a separate work package of the Starworms project (STop
Anthelmintic Resistant Worms; www.starworms.org). The main objective of the project is to
strengthen the monitoring and surveillance of drug efficacy and AR in programs aimed at
eliminating and controlling STH infections in humans.
This document describes the rationale, specific objectives and methods/design, and dis-
cusses the expected output and challenges for work package 1 of the Starworms trial which
aimes to evaluate stool-based diagnostic methods to assess drug efficacy and BZ resistance
markers to assess the emergence of AR. For more details on the other work packages, we refer
to the project website [26].
Introduction to work package 1
Currently, the reduction in number of eggs excreted in stool after drug administration (egg
reduction rate, ERR) is the recommended method for monitoring the efficacy of anthelmintic
drugs against STHs [27]. In contrast to other available assays, it allows for the assessment of
the efficacy of any drug against all STHs [28–31].
Today, a variety of egg counting methods have been recommended by WHO for the assess-
ment of drug efficacy [27], of which Kato-Katz thick smear is the most commonly applied. Egg
counting still requires a minimum amount of laboratory equipment and experienced labora-
tory technicians to ensure quality of the data obtained [22, 24, 32]. Furthermore, it is essential
that samples are analysed quickly after collection to ensure the visualisation of hookworm eggs
and that results are adequately analysed, applying the most appropriate summary statistics [15,
27] and are then reported to the responsible authorities. There is often limited availability of
laboratory capacity and a poor reporting of the results obtained. This prompts the need for an
improved diagnostic method that enables (i) egg counts to be performed without the use of a
microscope, (ii) automated egg counting, and (iii) submission of results from remote locations
via the internet for quality control of egg counts, analysis and reporting. Such a method would
eliminate the need for a microscope or highly skilled technicians/clinicians or administrators
while providing and centralizing drug efficacy results.
A method that largely meets this target product profile is the FECPAKG2 platform.
Recently, it has been launched as a complete remote-location diagnostic method for sheep/cat-
tle farmers and their veterinarians to assess the intensity of helminth infections and efficacy of
drugs [33]. The platform accumulates helminth eggs into one microscopic view after which
digital images are taken [34]. Images are stored by the associated software and can be uploaded
to a remote server when an Internet connection is available. Later, a web-based laboratory
technician can count the eggs visible in the images, after which the results are returned to the
user by e-mail. The FECPAKG2 platform thus potentially eliminates the need for skilled techni-
cians on-site. The online software allows easy access for quality control of egg counting and
the production of standardized analysis and reports. More importantly, it opens the door to
automated egg counting by egg recognition software [35]. Recently, Ayana et al. (in press) [36]
modified and optimized a FECPAKG2 protocol for the detection and quantification of human
STH eggs in stool. However, it remains unclear whether it provides equivalent ERR results to
those obtained by diagnostic methods recommended by WHO, and whether it would result in
more efficient use of financial and technical resources under field conditions.
From a research perspective, there is a growing interest to apply quantitative polymerase
chain reaction (qPCR) for the assessment of drug efficacy. In contrast to the egg counting
Stool-based diagnostics and molecular markers to assess reduced efficacy and resistance
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methods, qPCR can differentiate the different hookworm species, and thus allow evaluation of
BZ efficacy against the different hookworm species [37, 38]. This is of particular interest given
that there could be differential susceptibility towards BZ drugs among hookworm species, and
that there is increasing evidence of zoonotic transmission of Ancylostoma ceylanicum between
dogs and humans [39–42]. Although studies have linked amount of DNA with egg output [37,
43], to date, qPCR has not yet been applied for the assessment of drug efficacy.
Early detection of BZ resistance is essential to anticipate the efficacy of drugs in STH con-
trol programs, as it is more difficult to mitigate the spread of AR when the initial frequency is
already high [44]. However, both in vivo (e.g. ERR) and in vitro assays (e.g. egg hatch assay)
lack the sensitivity to detect the emergence of AR at an early stage. For example, in animals
ERR was only able to detect AR when the proportion of resistant STHs exceeded 25% [45], a
proportion that may impede mitigating the spread of AR. A more sensitive alternative is a
molecular test based on resistance-associated mutations in targeted genes. Due to the unfortu-
nate and costly experiences of AR in veterinary medicine, BZ resistance has been researched in
detail in animal STHs, providing strong evidence of molecular markers associated with BZ
resistance. An overview of the markers for BZ resistance in animal STH is provided by Von
Samson-Himmelstjerna et al., [46].
Generally, BZ resistance in animal STHs is caused by single nucleotide polymorphisms
(SNPs) in the gene encoding β-tubulin at codons 167 (TTC to TAC), 198 (GAA to GCA) or
200 (TTC to TAC), but the relative association of these SNPs with BZ resistance varies consid-
erably across animal STH species [47–49]. Various methodologies to detect and quantify these
SNPs in animal STH have been developed through an international Consortium for Anthel-
mintic Resistance SNPs (CARS), [50] of which some have now also been developed and
applied for human STHs [29, 30, 51–53]. The few studies assessing SNPs in human STHs sug-
gest that (i) polymorphisms are predominantly found in codon 200, and (ii) that resistance-
associated mutations increased after drug administration (seen for T. trichiura), (iii) but that
there was no clear association with reduced drug efficacy. However, the results should be inter-
preted with caution. First, they were based on a small number of participants (ranging from 3
to 31 participants) across a limited number of geographical areas (Kenya, Haiti, Panama and
Tanzania). Second, STH data were collected applying a variety of study methodologies. For
example, the samples originated from a wide range spectrum of the population (pre-SAC, SAC
and adults) and were examined applying different egg counting methods (Kato-Katz thick
smear, McMaster egg counting method and FLOTAC), which makes comparison across stud-
ies difficult.
Most technologies to assess SNPs linked to BZ resistance are only available in well-equipped
laboratories. Recently, Rashwan et al., [54] published a loop-mediated isothermal amplification
(LAMP) assay for the assessment of β-tubulin polymorphisms in human STHs. Due to its sim-
plicity, ruggedness and low cost, LAMP could provide major advantages in detecting AR on-
site. However, the method needs to be further validated on field samples. Another strategy to
further reduce the operational costs is to apply a pooled examination strategy. Examination of
pooled stool has already proved to allow for reduction in technical and financial resources for
other egg counting methods such as Kato-Katz thick smear [55].
Study objectives
The overall aim of this study is to recommend the best diagnostic methods to monitor drug
efficacy and status of AR in STH programs. These will then be applied in work package 2 (the
establishment of a surveillance system to monitor the global patterns of drug efficacy and
emergence of AR in STH programs). The specific objectives are to:
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1. Assess equivalence of ERRs measured by Kato-Katz thick smear, Mini-FLOTAC and
FECPAKG2
2. Assess the diagnostic performance of Kato-Katz thick smear, Mini-FLOTAC, FECPAKG2
and qPCR
3. Assess the costs linked with assessing drug efficacy by Kato-Katz thick smear, Mini-FLO-
TAC and FECPAKG2
4. Provide proof-of-principle for qPCR to assess intensity of infection and drug efficacy
5. Assess associations between frequency of SNPs linked to BZ resistance measured by pyrose-
quencing and history of drug pressure and drug efficacy
6. Compare pyrosequencing and LAMP for the assessment of SNPs linked to BZ resistance
7. Assess pooling samples as a cost-saving strategy to determine infection intensity (qPCR)
and frequency of SNPs linked to BZ resistance (pyrosequencing and LAMP)
Methods
Ethics approval and consent to participate
The Starworms protocol has been reviewed and approved by the Institutional Review Board
(IRB) of the faculty of medicine of Ghent University, Belgium (Ref. No B670201627755). The
trial protocol was subsequently also reviewed and approved by the IRBs associated with each
trial site (Ethical Review Board of Jimma University, Jimma, Ethiopia: RPGC/547/2016;
National Ethics Committee for Health Research (NECHR), Vientiane, Lao PDR: 018/NECHR;
Zanzibar Health Research Council, United Republic of Tanzania: ZAMREC/0002/February/
2015 and the Institutional Review Board from Centro de Pesquisas Rene´ Rachou, Belo Hori-
zonte, Brazil: 2.037.205).
Parent(s)/guardians of participants will sign an informed consent document indicating that
they understand the purpose of and procedures required for the study and that they are willing
to have their child participate in the study. If the child is�5 years, he/she has to orally assent
in order to participate in the study. Participants of�12 years of age are only included if they
sign an informed consent document indicating that they understand the purpose of the study
and procedures required for the study and are willing to participate in the study.
General design of the field trials
A series of drug efficacy trials will be performed in four STH endemic countries (Brazil, Ethio-
pia, Lao PDR and Tanzania). These trials will be designed to assess the efficacy of a single oral
dose of 400 mg ALB against STH infections in SAC by a variety of stool-based diagnostic
methods. At the start of each trial, schools will be visited by the local principal investigator (PI)
and a team of field officers, who will explain the planned trial and sampling method to the
parents and teachers and the children. At baseline, SAC will be asked to provide a fresh stool
sample. All children that meet all inclusion criteria and none of the exclusion criteria (see
Table 1) will be enrolled in the study. They will be treated with a single oral dose of 400 mg
ALB under supervision. The ALB to be used in the different studies is manufactured by Glax-
oSmithKline and donated to WHO and originates from the same production batch (Batch Nr:
335726). All collected stool samples will be processed to determine the fecal egg counts (FECs;
expressed in eggs per gram of stool (EPG)) for each STH using Kato-Katz thick smear (single
and duplicate), Mini-FLOTAC and FECPAKG2. During baseline evaluation, only stool samples
Stool-based diagnostics and molecular markers to assess reduced efficacy and resistance
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found to contain at least 13 eggs on duplicate Kato-Katz or at least 15 eggs on Mini-FLOTAC
for at least one of the three STHs will be preserved for further molecular analysis. Fourteen to
21 days after drug administration, a second stool sample will be collected from all the children
that were excreting eggs of any STH at baseline based on Kato-Katz thick smear and Mini-
FLOTAC. Stool samples will be examined by Kato-Katz thick smear (single and duplicate),
Mini-FLOTAC and FECPAKG2. All follow-up samples will be preserved for further molecular
analysis. To gain insights into the operational costs for assessing drug efficacy, the time to pro-
cess stool with Kato-Katz thick smear, Mini-FLOTAC and FECPAKG2, and the time needed to
enter data and to draft reports will be assessed. The different steps of the trials are schematized
in Fig 1.
Study population
The study will focus on SAC (age 5–14) since they are the major target of PC programs target-
ing STH, and they usually represent the group with highest worm burdens for A. lumbricoides
and T. trichiura [56]. This study will be conducted in Ethiopia, Tanzania, Lao PDR and Brazil.
The selection of these sites is based on their experience in assessing drug efficacy [13, 15], eval-
uating the performance of diagnostic methods [57–59] and the availability of well-equipped
diagnostic facilities and skilled personnel, and PC history (Table 2).
Sample size calculation
A sample size was calculated to test the alternative hypothesis that FECPAKG2, Mini-FLOTAC
and single Kato-Katz thick smear provide equivalent drug efficacy results measured by ERRs
compared to a duplicate Kato-Katz thick smear. Given the differences in drug efficacy of ALB
across the STH species [15, 21] (Ascaris: ~99%, hookworms: ~96%, Trichuris: ~65%), a level of
equivalence that is acceptable for Trichuris may not be acceptable for Ascaris. Therefore, a spe-
cies-specific level of equivalence was used. For Ascaris the level of equivalence was set at
2.5-point percentage, for hookworms and Trichuris the level of equivalence was set at 5.0 and
10 point percentage, respectively. Both type I and II errors were set at 0.05.
To calculate the corresponding sample size for each of the STH species, we performed a
simulation study. This simulation study considered (i) variation in ERR and baseline FECs
across and within STH species, (ii) variation in FECs introduced by the egg counting process,
(iii) the paired ERR results across egg count methods, and (iv) a post-hoc correction for a pair-
Table 1. Inclusion and exclusion criteria to be followed during the recruitment of participants for the field trials.
Inclusion criteria Exclusion criteria
• Subject is 5–14 years of age
• Subject is otherwise in healthy condition (based on
medical history and physical examination)
• Parent(s)/guardian(s) of subject signed an informed
consent document indicating that they understand the
purpose of and procedures required for the study and
that they are willing to have their child participate in
the study
• Subject of�5 years has assented to participate in the
study
• Subject of�12 years has signed an informed consent
document indicating that they understand the purpose
of the study and procedures required for the study, and
are willing to participate in the study
• Subject has provided a stool sample of at least 9 grams.
• Subject has active diarrhoea (defined as the passage of
3 or more loose or liquid stools per day) at baseline or
follow-up.
• Subject has an acute medical condition or is
experiencing a severe concurrent medical condition
• Subject has a known hypersensitivity to ALB or MEB
• Subject has received anthelmintic treatment within 90
days prior to the start of the treatment
• Subject vomited within 4 hours following drug
ingestion.
• Subject is not able to provide a stool sample of min 9
grams at baseline or follow-up.
• Subject has not swallowed the entire tablet.
https://doi.org/10.1371/journal.pntd.0006912.t001
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Fig 1. A schematic overview of the different steps of the field trials.
https://doi.org/10.1371/journal.pntd.0006912.g001
Table 2. An overview of the countries, study sites and institutions involved in work package 1 of the Starworms project as well as their respective drug pressure and
the type of benzimidazole drug administered.
Country Study site Institution Drug Pressure � Drug
Brazil Americaniñas, Belo Horizonte Fiocruz—Research institute of Renê Rachou Low ALB
Ethiopia Jimma Town, Jimma Zone Jimma University Low ALB
Lao PDR Nam Bak, Luang Prabang National institute of public health Medium MEB
Tanzania Chake Chake, Pemba Public Health Laboratory—Ivo de Carneri High ALB
� The classification of the countries into the four levels of drug pressure was based on the reported national coverage of drug administration to preschool (preSAC) and
school aged children (SAC) for the last 5 years (2009–2014; Preventive Chemotherapy Database of the WHO). Very high drug pressure: coverage >80% for preSAC and
SAC for each of the last 5 years; moderately high: coverage >50% for preSAC and/or SAC for each of the last 5 years; moderate: coverage >30% for preSAC or SAC for
each of the last 5 years; low: coverage is <30% for both preSAC and SAC for each of the last 5 years.
https://doi.org/10.1371/journal.pntd.0006912.t002
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wise comparison. Based on the simulation, at least 110, 100 and 12 complete cases are required
for Trichuris, hookworm and Ascaris, respectively. A detailed description of the sample size
calculation is available in the supplementary information (S1 Info).
Laboratory procedures
We will provide participants with a container for the collection of stool samples. The samples
will be collected and stored in cooler boxes with ice-packs, which will then be transported to
the laboratory at the respective study site for further analysis. Upon arrival in the laboratory,
samples will be thoroughly homogenized using a wooden spatula to obtain a more homoge-
neous distribution of STH eggs in the stool [60]. A detailed standard operating procedure
(SOP) on sample homogenisation is available in the supplementary information (S2 Info).
Egg counting methods
Kato-Katz thick smear. Kato-Katz thick smears will be prepared on microscope slides
using a square template with a hole of 6 mm diameter and 1.5 mm deep, which is assumed to
sample 41.7 mg of stool [61]. Two Kato-Katz thick smears will be prepared per sample (slide A
and B) and to avoid clearing of hookworm eggs, all slides will be examined within 30–60 min
for the presence of STH eggs. The number A. lumbricoides, T. trichiura and hookworm eggs
will be counted and recorded per slide. Slide A will represent a single Kato-Katz thick smear.
For the duplicate Kato-Katz thick smear, the egg counts of slide A and B are added and multi-
plied by 12 to obtain the FEC. A detailed SOP on how the duplicate Kato-Katz thick smears
will be processed is provided in S3 Info.
Mini-FLOTAC method. The Mini-FLOTAC method will be performed as described ear-
lier [62]. In short, the sample recipient of the Fill-FLOTAC will be filled with fresh stool. Sub-
sequently, the stool will be thoroughly homogenized with 38 ml of flotation solution (FS)
(saturated salt solution, density = 1.20). The suspension will then be filtered through the inte-
grated Fill-FLOTAC filter, and transferred into the two chambers of the Mini-FLOTAC
device. After 10 minutes, the top part of the chambers will be translated, and both chambers of
the Mini-FLOTAC device will be screened for the presence of STH eggs under a light micro-
scope using a 100x magnification. The number of eggs in both Mini-FLOTAC chambers com-
bined will be counted and recorded for A. lumbricoides, T. trichiura and hookworm,
separately. A detailed SOP on the Mini-FLOTAC method can be found in the supplementary
information (S4 Info).
FECPAKG2 method and automated egg counting. Ayana et al. (in press) [36] describes
the FECPAKG2 method for counting STH eggs in human stool. Stool analysis starts by weigh-
ing 3 grams of fresh stool in a Fill-FLOTAC. Subsequently, the stool will be homogenized in
tap water. Afterwards, the stool suspension will be transferred to the FECPAKG2 sedimenter
and additional tap water will be added to the sedimenter (approximately 200 ml). The sedi-
menter will be inverted 3 times to mix the solution, after which it will be placed on an even sur-
face at room temperature to allow STH eggs to sediment. The next day, the supernatant will be
poured off and 80 ml FS will be added to the remaining slurry (15 ml) that is being retained in
the bottom of the sedimenter by the plastic dam. The whole content of the sedimenter will
then be poured into a FECPAKG2 filtration unit. The closed FECPAKG2 filtration unit will be
inverted three times before transferring 455 μl of the suspension into each of the 2 wells of the
cassette. Between each sampling, the cylinders will be inverted three times to homogenize the
solution. After filling the wells, the cassette will be placed on a horizontal surface for a mini-
mum of 20 minutes to allow accumulation of the STH eggs around the tip of the rod that is
present in the centre of each well of the FECPAKG2 cassette. Subsequently, the cassette will be
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placed in a Micro-I device for image capture, which will be connected to a laptop or desktop
computer. The device automatically images both wells. The digital images of the wells will be
stored on the laptop / computer and will be uploaded to the main FECPAKG2 server when an
Internet connection is available. After the imaging step, the cassettes will be emptied and
rinsed with tap water for reuse. To count the eggs, sample images and details (sample ID, sam-
ple collection date, study site, etc.) will be uploaded from the server. Finally, the mark-up tech-
nician will identify and count any STH eggs present in the images using specialized software
developed for this purpose. Results of the mark-up will be saved and stored automatically for
reporting and analysis. Detailed SOPs on how to perform the FECPAKG2 and to mark-up the
images are available in S5 Info. Stored images will also be submitted for analysis by specialized
image processing software originally designed to detect and quantify helminth eggs in waste
water [35].
Quality control egg counting procedure. A predefined, randomly selected subset of sam-
ples (10% of the total number of samples) will be re-evaluated by each of the three egg count
methods. To this end, a senior researcher, who is blinded to the initial FECs, will re-count STH
eggs across all three egg count methods. A third examiner will re-count STH eggs in case of dis-
crepancies. Discrepancies are defined as (i) false negatives/positives, (ii) difference in egg counts
>10 when the total number of eggs counted�100 or (iii) difference in egg counts>20% when
more than 100 eggs are counted [24]. A detailed SOP on the performance of quality control for
the egg counting methods is provided in the supplementary information (S6 Info).
DNA-based methods
Stool preservation and DNA extraction. After performing the egg counting methods,
stool samples will be preserved. At baseline, only those samples in which a sufficient number
of eggs are counted for at least one STH species will be preserved (duplicate Kato-Katz thick
smear: 13 eggs; Mini-FLOTAC: 15 eggs). At follow-up, all samples will be preserved, and this
regardless of the number of STH eggs found. For each sample, 2 subsamples of 0.5 g will be
preserved in 1 ml of absolute ethanol. A detailed SOP on sample preservation is provided in
the supplementary information (S7 Info). Preserved samples will be stored in sample boxes at
room temperature and shipped to Belgium for DNA extraction and subsequent molecular
analysis. The DNA extraction protocol will be run on the automated QiaSymphony using a
preceding mechanical lysis step by means of bead beating. This DNA protocol maximizes STH
DNA yield from stool (Ayana et al, in preparation). DNA extraction will be performed at
Ghent University (Belgium) and Elizabeth Tweesteden Hospital (The Netherlands). S8 Info
provides a detailed SOP on DNA extraction.
qPCR. All DNA extracts will be analyzed for the presence of A. lumbricoides, T. trichiura,
N. americanus and A. duodenale DNA using qPCR assays previously described [37, 63, 64]. S9
Info provides a detailed SOP on how we will perform the qPCR. The output of the qPCR analy-
sis will be expressed in genome equivalents (GE) per ml DNA extract.
Pyrosequencing. In two subsets of the DNA samples, we will apply a previously described
pyrosequencing protocol [30, 52] to determine frequency of mutant SNPs in the three codons
of the ß-tubulin associated with BZ resistance. The first subset will consist only of baseline
DNA samples, and will be used to assess the association between drug pressure history and the
corresponding frequency of mutant SNPs linked to BZ resistance. Per study site, 60 baseline
DNA samples positive for each STH species (Ascaris, Trichuris and hookworm) will be ran-
domly selected from the available baseline DNA samples. To avoid these samples representing
one school or one level of individual response to ALB, selection of the samples will be propor-
tionately to the total number of cases per school and individual drug response (Table 3).
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We will use a second set of DNA samples to assess the association between individual
responses to ALB by pyrosequencing the ß-tubulin gene. At each site, samples from at least 30
participants who were cured (baseline samples only) and from at least 30 participants who
were still excreting eggs at follow-up (both baseline and follow-up samples) will be selected for
each STH species separately. Participants which still excreted eggs will be stratified, into
‘responders’, ‘poor responders’ and ‘non-responders’. This stratification will be based on
WHO thresholds used for classifying the efficacy into ‘satisfactory’ (‘responders’), ‘doubtful’
(‘poor responders’) and ‘reduced’ (‘non-responders’) [27] (Table 3). A total of 10 participants
will be randomly selected for each stratum. Total DNA will be extracted from these stool sam-
ples and sent for pyrosequencing at McGill University (Canada).
LAMP. A previously described LAMP protocol [65] will be applied on a subset of 300
DNA samples that are withheld for pyrosequencing. The selection of these samples will be
based on the frequency of SNPs linked to AR. Based on the pyrosequencing results, samples
will be classified into four levels of SNP frequency, including absence of SNP linked to BZ
resistance, and low, moderate and high frequency of SNPs linked to BZ resistance. The thresh-
olds used to define the last three levels of frequency of SNPs will be based on the 1st and 3rd
quartile of the frequency of SNP across all the samples, in which SNP linked to BZ resistance
are present. Samples in which the frequency of a SNP for BZ resistance is higher than 0% but
lower than the 1st quartile will be classified into the low frequency group, samples in which the
frequency of a SNP for BZ resistance is at least equal to the 3rd quartile will be classified into
the high frequency group. All other samples, in which SNPs linked to BZ resistance are found,
will be classified into the moderate frequency group. For each STH species (Ascaris, Trichuris,
and hookworms), 25 samples in each level of SNP frequency will be randomly selected and
processed with the LAMP assay. The LAMP will be performed at McGill University (Canada)
and at two study sites (Ethiopia and Tanzania).
Pooling stool samples for DNA-based diagnostic methods. For both qPCR and pyrose-
quencing/LAMP, pooled samples will be analyzed. For qPCR, aliquots of all stool samples pre-
served for further molecular analysis will be pooled into pools of 10, 20 and 60 individual
samples. The procedure to pool stool was adapted from Mekonnen et al., [66]. A detailed SOP
on sample pooling is available in supplementary information (S10 Info). For pyrosequencing
and LAMP, only samples that are withheld for pyrosequencing will be pooled into pools of 10
individual samples. All downstream processes (DNA extraction extracted, qPCR and pyrose-
quencing/LAMP) will be performed as described in aforementioned sections.
Cost analysis of the different diagnostic methods
To make objective estimates of the costs associated with the different diagnostic methods, we
will collect data on the cost of the materials used as well as the time required to prepare and
examine stool samples for the different stool-based diagnostic methods.
Assessing costs of reagents and materials
Detailed pricing information for the list of materials needed to perform Kato-Katz thick smear
and Mini-FLOTAC will be obtained from the local PI. The costs for the materials needed for
Table 3. Classification of the individual response to a single oral dose 400 mg ALB against STH based on the individual egg reduction rate (iERR).
STH Cured Responder Poor responder Non-responder
Ascaris iERR = 100% iERR� 95% 85%� iERR < 95% iERR < 85%
Trichuris iERR = 100% iERR� 50% 40%� iERR < 50% iERR < 40%
Hookworms iERR = 100% iERR� 90% 80%� iERR < 90% iERR < 80%
https://doi.org/10.1371/journal.pntd.0006912.t003
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the FECPAKG2 method will be obtained from the manufacturer (Techion Group Ltd.) and is
expected to be the same for all four study sites. A list of materials included in the cost calcula-
tion for the Kato-Katz thick smear and Mini-FLOTAC method is provided in S11 Info. The
costs associated with molecular analysis of the samples will include the cost for preservation
and shipment of the stool samples as well as the laboratory materials used to perform DNA
extractions and qPCR.
Timing of diagnostic methods
Timers will be provided to each laboratory technician to measure the time needed to perform
the different steps of each of the diagnostic methods. For all egg counting methods, the time
taken to complete each step will be measured. In addition, the time needed for data entry and
drafting a report will be recorded. The protocols of the egg counting methods include more
details on the different timing steps (S3–S5, S8 and S10 Info).
Data management
All data collected during the studies will be recorded in specifically designed record forms (S12
Info). The original results written down on the paper documents will be scanned and stored
digitally. This data will later be entered into customized Excel-files by two separate individuals
(S13–S15 Info). After completion of the data entry, the files of both data entry clerks will be
compared for discrepancies (S16 Info). Potential mismatches will be highlighted and the true
values verified using the scanned original record form.
Study management and coordination
The PIs from each site are responsible for acquiring ethical approval by their local Institutional
Review Board (IRB) and conducting the trial procedures as described in the original study pro-
tocol and study SOPs. The studies in the different countries will be coordinated by the project
PI and the Starworms Coordinating Team at Ghent University. One week prior to the start of
each study, a member of the Starworms Coordinating Team will visit the study site. Local team
members will be informed on the study design, familiarised with the different study docu-
ments and receive both theoretical and practical training on how to perform different egg
counting methods according to the Starworms SOPs. The Starworms staff member will remain
on-site for at least 7 days after the start of the trial to ensure SOP adherence and to solve any
issues that might arise.
Statistical data analysis
After data collection and quality control, all data will be combined in a final, protected dataset
for statistical analysis. After finishing work package 1, this dataset will be made available on
the Starworms website (www.starworms.org). All statistical analysis will be performed in R (R
Development Core Team, 2016).
Assessment of the impact of previously conducted PC in reducing STH
morbidity
We will evaluate both the prevalence and intensity of each different STH species in each of the
four different study sites. The percentage of individuals included in the different classes of
infection intensity will be reported in order to assess the efficacy of the PC intervention con-
ducted until then in eliminating STH infection of moderate and heavy intensity.
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Assessment of the equivalence of egg reduction rates measured by Kato-
Katz thick smear, Mini-FLOTAC and FECPAKG2
We will report the efficacy of a single oral dose of 400 mg ALB separately for A. lumbricoides, T.
trichiura and hookworms, and for each FEC method by means of ERR, using the formula below:
ERR ¼ 100%� ðarithmetic meanðFEC at baselineÞ
  arithmetic mean ðFEC at follow   upÞÞ=ðarithmetic meanðFEC at baselineÞÞ
A bootstrap analysis will be used to determine the corresponding 95% confidence intervals
(95% CI) for each egg counting method and for the pair-wise differences in ERR across diag-
nostic methods. A permutation test will be used to assess the equivalence in ERR between a
duplicate Kato-Katz thick smear, and a single Kato-Katz thick smear, Mini-FLOTAC and
FECPAKG2. Tukey’s method will be applied for multiple comparison between methods. In
addition, the agreement between a duplicate Kato-Katz thick smear and the other egg counting
methods in the assignment of drug efficacy into ‘satisfactory’, ‘doubtful’ and ‘reduced’ will be
evaluated by Fleiss’ kappa statistic (κFleiss). This classification of the drug efficacy will be based
on the criteria recently proposed by the WHO (Table 4) [27]. The value of this statistic indi-
cates a slight (κFleiss <0.2), fair (0.2� κFleiss <0.4), moderate (0.4� κFleiss <0.6), substantial
(0.6� κFleiss <0.8) and an almost perfect agreement (κFleiss� 0.8).
Assess the diagnostic performance of Kato-Katz thick smear, Mini-
FLOTAC, FECPAKG2 and qPCR
For each diagnostic method, the sensitivity will be calculated using the combined results of the
four methods (duplicate Kato-Katz thick smear, Mini-FLOTAC, FECPAKG2 and qPCR) as the
diagnostic ‘gold’ standard. This means that a sample is considered positive if it tested positive on
at least one of the four methods. The species specificity of all methods will be set at 100%, as
indicated by the morphology of the eggs or by the species-specific primer sets used in qPCR.
The corresponding 95% CI for sensitivity will be calculated separately for each diagnostic
method. Differences in sensitivity between methods will be assessed by a permutation test
(10,000 iterations). Tukey’s method will be applied for pair-wise comparisons between the meth-
ods. The impact of infection intensity on the sensitivity within each method will be explored by
a logistic regression model, which will be fitted for each of the methods with their test result
(positive/negative) as the outcome and the natural log transformed mean FEC across the three
methods as covariate. The predictive power of the final models will be evaluated by the propor-
tion of the observed outcome that was correctly predicted by the model. To this end, an individ-
ual probability >0.5 will be set as a positive test result, and negative if different. Finally, the
sensitivity for each of the pre-defined values of FEC will be calculated based on these models.
Intensity of infection
For egg counting methods, the agreement in egg counts will be evaluated by permutation tests
(10,000 iterations) based on (i) Pearson’s correlation coefficient and (ii) the differences in FECs.
Table 4. Classification of the efficacy of a single oral dose 400 mg albendazole against STH.
STH Satisfactory Doubtful Reduced
Ascaris ERR� 95% 85%� ERR < 95% ERR < 85%
Trichuris ERR� 50% 40%� ERR < 50% ERR < 40%
Hookworms ERR� 90% 80%� ERR < 90% ERR < 80%
https://doi.org/10.1371/journal.pntd.0006912.t004
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Tukey’s method will be applied for pair-wise comparisons within each STH species. For qPCR,
the agreement in GE numbers and FECs obtained by duplicate Kato-Katz thick smear will be
evaluated by permutation tests (10,000 iterations) based on Pearson’s correlation coefficient.
Samples containing helminth eggs will be classified into low, moderate, and heavy infection
intensity according to FECs obtained by duplicate Kato-Katz and following the thresholds pro-
posed by WHO; for A. lumbricoides these are 1–4,999 EPG, 5,000–49,999 EPG, and>49,999
EPG; for T. trichiura these are 1–999 EPG, 1000–9,999 EPG, and>9,999 EPG; and for hook-
worm these are 1–1,999 EPG, 2,000–3,999 EPG and>3,999 EPG (WHO, 1998). For each of
the other diagnostic methods, a receiver operating characteristic analysis will be performed to
determine the corresponding FECs / GE numbers that allow classification of the infections
into low, moderate and heavy using duplicate Kato-Katz thick smear as a reference. Finally,
the proportion samples correctly classified as having a low, moderately and heavy infection
intensity will be assessed separately for single Kato-Katz thick smear, Mini-FLOTAC, FEC-
PAKG2 and qPCR.
Estimate the costs linked to the assessment of drug efficacy by Kato-Katz
thick smear, Mini-FLOTAC and FECPAKG2
The mean time to process and examine one stool sample will be calculated for each separate
egg counting method. We will also calculate the mean time needed to enter the demographic
data and test results of a single subject, and the time to analyze and report the data. To reach
an estimation of the total cost associated per sample, we will combine these data with the esti-
mation of the costs of the raw materials and labour time needed to analyze a sample by each of
the different methods. To calculate the costs for analysing samples a fixed rate will be used.
Finally, a one-way sensitivity analysis will be performed to assess the impact of each parameter
on the total cost for each diagnostic method separately.
Provide proof-of-principle for qPCR to assess infection intensity and drug
efficacy by means of reduction in GE
The efficacy of a single oral dose of 400 mg ALB will be reported separately for A. lumbricoides,
T. trichiura and hookworms by means of genome equivalent reduction rate (GERR), using the
formula below: GERR = 100% x (arithmetic mean(GE at baseline)–arithmetic mean (GE at fol-
low-up)) / (arithmetic mean (GE at baseline)).
The corresponding 95% CI for GERR will be determined by bootstrap analysis (10,000 iter-
ations). A permutation test will be used to assess the equivalence in drug efficacy between a
duplicate Kato-Katz thick smear by means of ERR and qPCR by means of GERR for each of
the STH species separately. The same level of equivalence will be applied as described in sec-
tion 4.8.1. In addition, the agreement between a duplicate Kato-Katz thick smear and qPCR in
the assignment of drug efficacy into ‘satisfactory’, ‘doubtful’ and ‘reduced’ will be evaluated by
κFleiss statistic.
Assess associations between frequency of SNPs linked to BZ resistance
measured by pyrosequencing and history of drug pressure and drug
efficacy
To assess the association between mutant SNPs linked to BZ resistance and history of drug
pressure, a permutation test will be applied to evaluate differences in frequency of mutant
SNPs linked to BZ in the baseline samples across the study sites. Tukey’s method will be
applied for pair-wise comparisons between the study sites.
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To assess the association between mutant SNPs linked to BZ resistance and drug efficacy, a
permutation test will be applied to evaluate any difference in frequency of mutant SNPs linked
to BZ across the four levels of individual response to ALB (Table 3). Tukey’s method will be
applied for pair-wise comparisons between the four levels of individual response.
Compare pyrosequencing and LAMP for the assessment of SNPs linked to
BZ resistance
The sensitivity of the LAMP method to detect mutant SNPs linked to BZ resistance will be
evaluated using the pyrosequencing method as the gold standard. The impact of SNP fre-
quency on the sensitivity of LAMP will be explored by a logistic regression model with the
LAMP result as outcome (negative/positive) and the frequency of SNPs linked to BZ resistance
as covariate. The predictive power of the final models will be evaluated by the proportion of
the observed outcome that was correctly predicted by the model. To this end, an individual
probability >0.5 will be set as a positive test result, and negative in all other cases. The sensitiv-
ity for each of the pre-defined values of FEC will be calculated based on these models.
Finally, the κ-statistic will be determined to assess the agreement in the LAMP test result
across the different study sites, Canada (McGill University), Ethiopia (Jimma University) and
Tanzania (Public Health Laboratory—Ivo de Carneri)). The value of this statistic indicates a
slight (κ<0.2), fair (0.2� κ<0.4), moderate (0.4� κ<0.6), substantial (0.6� κ<0.8) and an
almost perfect agreement (κ� 0.8).
Assess pooling samples as a cost-saving strategy to determine infection
intensity (qPCR) and occurrence of SNPs linked to BZ resistance
(pyrosequencing and LAMP)
For qPCR, we will apply the Pearson’s correlation coefficient to assess the agreement between
the mean frequency of GE number based on the examination of individual samples and the
GE based on the examination of pooled samples will be evaluated. In addition, a permutation
test (10,000 iterations) will be applied to test for differences in mean GE number between the
examination of individual and pooled samples.
For pyrosequencing, the agreement between the mean frequency of SNPs based on the
examination of individual samples and the frequency of SNPs based on the examination of
pooled samples will be evaluated by the Pearson’s correlation coefficient. In addition, a permu-
tation test will be applied to test for differences in mean frequencies between examination of
individual and pooled samples.
For LAMP, the κ-statistic will be determined to assess the agreement in the LAMP test
results obtained by an individual and a pooled examination strategy. The impact of SNP fre-
quency on the sensitivity of LAMP will be explored by a logistic regression model with the
LAMP result as outcome (negative/positive) and the frequency of SNPs linked to BZ resistance
as covariate. The predictive power of the final models will be evaluated by the proportion of
the observed outcome that was correctly predicted by the model. To this end, an individual
probability >0.5 will be set as a positive test result, and negative in all other cases. The sensitiv-
ity for each of the pre-defined values of SNP frequency will be calculated based on these
models.
Discussion
The potential development of AR is a real threat for PC programs targeting STHs. It is facili-
tated by the ever-increasing quantity of anthelmintic drugs reaching at risk populations, the
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administration of drugs with the same mode of action at a suboptimal dose and the lack of
alternative treatment options should AR eventually emerge and spread. It is therefore of
paramount importance that the efficacy of the administered BZ drugs is regularly moni-
tored. However, in order to establish a robust surveillance system to monitor drug efficacy
there is a need for diagnostic methods that effectively mitigate important obstacles of per-
forming, analysing and reporting drug efficacy surveys in resource poor settings, and a vali-
dated molecular marker to detect emergence of AR at an early stage. Based on the results
from this study within the Starworms project, we aim to recommend diagnostic methods to
monitor drug efficacy and molecular markers to assess the status of AR in STH control
programs.
We will be the first to report a comprehensive comparison of two novel egg counting meth-
ods (Mini-FLOTAC and FECPAKG2) and DNA-based methods (qPCR) with the current
WHO diagnostic standard (Kato-Katz thick smear). We will not limit our comparison to the
diagnostic performance but expand our analysis to compare them for the intended use-case
(assessment of drug efficacy by means of egg reduction rate) and consider the associated costs
and time required to perform each of the different methods.
The inclusion of FECPAKG2 may create a game-changing shift in how drug efficacy can be
monitored at a global scale. The online connectivity of FECPAKG2 allows easy access for qual-
ity control of egg counts and the production of standardized analysis and reports. It also opens
the door to automated egg counting by egg recognition software, which when successful, could
further increase throughput, reduce personnel costs and variation in egg counts between tech-
nicians or laboratories. We will provide proof-of-principle for qPCR to assess infection inten-
sity and drug efficacy by means of GE numbers. Inclusion of qPCR will also allow for more
accurate estimates of the sensitivity of the different diagnostic tests. This is of particular impor-
tance since there is no gold standard diagnostic method for STHs [67].
By standardizing the drug efficacy trials (e.g., egg count method, follow-up period, anthel-
mintic drug and statistical analysis) and strategically selecting the study sites (varying drug
pressure history, and hence possibly differences in drug efficacy), we hope to provide comple-
mentary insights into SNPs in the β-tubulin gene as a marker for BZ resistance in human
STHs. If these SNPs play a role in AR, we expect an increase in frequency in mutant SNPs in
STHs as a function of increased drug pressure history and decreased individual response to
treatment. However, this molecular part of the study may face some challenges, which may
impede a straightforward interpretation of the results. First, if the expected trends in SNPs are
not detected, it is not possible to completely exclude them as a marker for BZ resistance. Fur-
thermore, it could also indicate that resistance to BZ has not yet emerged, which would also
jeopardize any downstream objectives (e.g. comparison of pyrosequencing and LAMP for the
assessment of SNPs linked to BZ resistance and assessing pooling samples as a cost-saving
strategy to determine the frequency of SNPs linked to BZ resistance). It is also important to
note that any observed trends would only suggest an association rather than causal relation-
ship. Second, it remains unclear whether we will be able to select the number of cases per level
of individual response for each of the different STH species. Finally, the classification of the
individual response is based on the outcome of imperfect tests (sub-optimal sensitivity), fur-
ther complicating the interpretation.
To conclude, the combined results of this study are expected to answer a number of out-
standing questions with regards to how to best monitor drug efficacy and measure AR in pop-
ulations that are being subjected to PC for STH infections. The results could be translated into
novel recommendations for the scientific community on what is the best diagnostic method to
assess drug efficacy in ongoing control programs and will create the basis to set up a robust
surveillance system.
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